Authorization and medical necessity required

Services must meet authorization and medical‑necessity guidelines for the procedure, diagnosis, and the member’s state of residence; coverage does not guarantee reimbursement. Providers are responsible for submitting accurate documentation and correct coding; failure to follow coding/billing guidelines or to provide accurate/incomplete documentation may lead to claim denial or recoupment.

• Coverage determinations depend on individual benefit coverage at time of request (see Applicable State and Federal Regulations).
• Follow standard coding guidelines (CPT, ICD‑10, CMS NCCI, etc.).

Prior authorization — none stated in excerpt

The policy text does not state any specific prior‑authorization program or codes that always require prior authorization in this excerpt. Verify payer‑specific prior authorization rules before ordering specialized assays.

• No explicit universal prior authorization requirement is listed in the policy text.
• Confirm payer or network prior‑auth requirements for individual members.

Prior authorization not specified — follow CDC recommendations for testing

The document does not specify uniform prior‑authorization requirements for the tests described; clinicians should follow CDC guidance for test selection and specimen timing and verify member benefits and payer rules when ordering tests.

• Testing selection and timing guidance aligned to CDC recommendations (e.g., NAAT/NS1 ≤7 days for dengue).
• Confirm member eligibility and payer rules before testing.

Validated laboratory testing required

Use only laboratory tests that have undergone independent comprehensive assessment of quality, safety, and performance, and perform testing in appropriately equipped laboratories by trained staff.

• WHO: “Only laboratory tests that have undergone independent, comprehensive assessment of quality, safety and performance should be used.”
• Perform testing in appropriately equipped labs by trained personnel.

Potential prior authorization for listed test codes — verify payer rules

Certain molecular, serologic, antigen, and specialized assays are enumerated with CPT/HCPCS codes in the policy; providers should verify whether payer prior‑authorization is required for any listed CPT/HCPCS codes before ordering.

• Examples of listed codes include 86794 (Zika IgM), 87478 (Ehrlichia NAAT), 87798 (amplified probe), and proprietary TBRF immunoblots (87899).
• Confirm payer prior‑auth requirements per member and contract.

Prior authorization not specified in reference/publication sections

The reference and publication‑history sections in the excerpt do not list any additional prior‑authorization requirements.

• Publication history shows governance approval on 06/16/2026.
• No further prior‑auth triggers are specified in the referenced sections.

Step therapy / testing sequence — no formal step‑therapy

No formal step‑therapy rules are described in the policy; clinical guidance recommends preferred diagnostic approaches (e.g., NAAT/PCR early in illness, serology or paired sera for confirmation, blood smear for malaria/babesia) but these are not framed as enforced step‑therapy.

• Example: PCR/NAAT is preferred within the first week for Anaplasma/Ehrlichia; serology (paired acute and convalescent) is required for rickettsial confirmation.
• Two‑tier Lyme algorithm is clinical guidance (see Lyme testing sequence) rather than a payer step‑therapy requirement.

Lyme testing sequence — two‑tier testing required

For suspected Lyme disease, follow two‑tier testing: perform an EIA (or other screening EIA) and only perform supplemental IgM/IgG immunoblot or supplemental EIAs if the initial EIA is positive or equivocal; do not perform immunoblot unless the screening EIA is positive or equivocal.

• Two‑tier testing is the recommended sequence for early disseminated/late Lyme disease (acute/convalescent sera optimal).

Step therapy — none specified

The policy explicitly states there are no step‑therapy requirements specified in this section.

• Clinical guidance on diagnostic choices is provided but not framed as an enforced step‑therapy policy.

Step therapy — none specified in these chunks

Clinical guidance in the cited chunks likewise indicates no step‑therapy mandates for the tests discussed.

• Providers should follow clinical algorithms and CDC/IDSA guidance rather than an insurer‑imposed step therapy sequence for these diagnostics.

Documentation and applicability — providers must document services accurately

Providers are responsible for submitting accurate documentation of services performed; application of the policy criteria depends on the individual’s benefit coverage and the facts of the case.

• Ensure documentation supports medical necessity for the ordered test and ties specimen timing/type to clinical presentation.
• Coverage determinations depend on the member’s benefit coverage at time of request.

Specimen and testing modality notes — document specimen type and modality

The policy text describes testing modalities and specimen types (serum, whole blood, tissue, CSF, urine, FFPE) relevant to test selection but does not prescribe specific submission or billing forms; document the specimen type used and the testing modality selected.

• Types of testing discussed include NAAT, IFA, blood smear, culture, darkfield microscopy, and serology.
• No explicit specimen submission rules are provided in these chunks.

Specimen timing and type must be documented

Document the timing of specimen collection and the specimen type used (e.g., acute vs convalescent serum, whole blood, CSF, urine) because interpretation and confirmation depend on specimen timing and type (for example, NAAT/NS1 for dengue is most useful ≤7 days after symptom onset).

• CDC: paired sera and timing affect confirmatory interpretation (e.g., babesiosis and rickettsial diseases).
• NAAT/NS1 for dengue and many arboviruses is most sensitive ≤7 days after symptom onset.

Specimen and timing documentation — record specimen type and timing

Document specimen type and timing relative to symptom onset (for example, serum, CSF, urine; collect dengue/Zika NAAT on serum ≤7 days after symptom onset; consider urine for Zika NAAT).

• WHO recommends whole blood/serum/plasma routine testing for arboviruses and urine for Zika NAAT.
• Record symptom onset date and specimen collection date to support test interpretation.

Paired serology documentation — collect and document paired sera and fourfold rise

Paired acute and convalescent sera (collected ~2–4 weeks apart) are recommended for serologic confirmation for several infections (e.g., anaplasmosis/ehrlichiosis, RMSF, babesiosis) and documentation of a four‑fold rise in IgG titer should be provided when used for confirmation.

• CDC/AA P: a fourfold rise in antibody titer between acute and convalescent sera confirms recent infection.
• Document dates of both specimen collections and titer results on the claim/record.

Blood smear testing documentation — request manual smear review and document repeats

For suspected babesiosis or malaria, explicitly request manual review of Giemsa‑ or Wright‑stained blood smears and, if clinical suspicion persists after a negative initial smear, repeat smears every 12–24 hours for up to 72 hours as indicated; document that manual (nonautomated) review was requested.

• AA P: manual (nonautomated) review of blood smears should be requested explicitly for babesiosis.
• If initial malaria smears are negative but suspicion persists, repeat every 12–24 hours up to 72 hours.

Publication history note — governance date recorded (no extra provider documentation requirements)

Publication history shows governance approval on 06/16/2026; the publication history section does not impose additional provider documentation requirements in the excerpt.

• Policy origination/governance date: 06/16/2026.
• No further provider documentation rules are contained in the publication history chunk.

Denial risk for improper coding or documentation

Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and documentation is inaccurate or incomplete; ensure coding and clinical documentation justify the test ordered.

• Follow industry coding guidelines (CPT, ICD‑10, CMS NCCI, etc.).
• Support medical necessity with clinical notes, specimen type, collection timing, and lab results when submitting claims.

(No explicit provider‑facing authorization or billing denial triggers are present in these chunks of the excerpt.)

• The excerpt contains clinical/testing guidance and code lists but does not define specific denial triggers beyond general coding/documentation compliance.

Paired sera required for confirmatory serology — missing paired sera risks non‑confirmation

Failure to obtain paired acute and convalescent sera and to demonstrate a fourfold rise in antibody titer when required (e.g., rickettsial diseases, babesiosis) may prevent laboratory confirmation and could affect diagnostic interpretation and coverage decisions.

• CDC and AAP: a fourfold rise in IgG between acute and convalescent sera is required to confirm several tickborne infections.
• Document both specimen dates and titer changes when using serology for confirmation.

Flavivirus confirmation — confirm IgM/IgG screening positives with PRNT or reference testing

Initial antibody‑positive screening tests for flaviviruses (e.g., WNV, dengue, Zika) should be confirmed with a more specific test such as plaque reduction neutralization test (PRNT); failure to confirm antibody‑positive screening may result in inadequate diagnostic confirmation.

• CDC: antibody screening tests are considered screening only; PRNT is recommended to differentiate flavivirus infections and confirm IgM‑positive specimens.
• Specimens should be tested against other arboviruses active in the region or travel area.

Time‑sensitive PCR — perform Anaplasma/Ehrlichia PCR within first week

Perform PCR/NAAT for Anaplasma and Ehrlichia within the first week of illness because doxycycline therapy rapidly decreases PCR sensitivity; delayed testing after antibiotics may yield false‑negative PCR results.

• AAP/IDSA guidance: PCR sensitivity declines rapidly after initiation of doxycycline; collect whole blood for NAAT within first week.
• If PCR is negative but clinical suspicion remains, rely on paired serology for diagnosis.

Government policy precedence — follow applicable LCD/NCD/state Medicaid rules

If there is a conflict between this policy and an applicable government policy (for example, Medicare LCD/NCD or state Medicaid), the government policy will take precedence and will be used to make coverage determinations.

• Consult CMS LCD/NCD or state Medicaid rules when member coverage is governed by those programs.

(No explicit authorization or denial triggers are present in these document chunks beyond those already noted.)

• The publication history and references do not add provider‑facing denial triggers in the excerpt.